MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify pharmacodynamic biomarkers to support the clinical development of MCT inhibitors now in clinical trials. In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism in vitro and in vivo Exposing human lymphoma and colon carcinoma cells to AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux. AZD3965 also increased the levels of TCA cycle-related metabolites and 13C-glucose mitochondrial metabolism, enhancing oxidative pyruvate dehydrogenase and anaplerotic pyruvate carboxylase fluxes. Increased mitochondrial metabolism was necessary to maintain cell survival under drug stress. These effects were counteracted by coadministration of the mitochondrial complex I inhibitor metformin and the mitochondrial pyruvate carrier inhibitor UK5099. Improved bioenergetics were confirmed in vivo after dosing with AZD3965 in mouse xenograft models of human lymphoma. Our results reveal new metabolic consequences of MCT1 inhibition that might be exploited for therapeutic and pharmacodynamic purposes. Cancer Res; 77(21); 5913-24. ©2017 AACR.

[1]  S. Horvath,et al.  MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. , 2016, Cell reports.

[2]  D. Altieri,et al.  Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy , 2015, Clinical Cancer Research.

[3]  J. Reis-Filho,et al.  Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival , 2015, The Journal of pathology.

[4]  K. Brindle.  Imaging metabolism with hyperpolarized (13)C-labeled cell substrates. , 2015, Journal of the American Chemical Society.

[5]  M. Leach,et al.  Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours , 2015, British Journal of Cancer.

[6]  N. Tunariu,et al.  Evaluation of lactate detection using selective multiple quantum coherence in phantoms and brain tumours , 2015, NMR in biomedicine.

[7]  J. Pouysségur,et al.  Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. , 2015, Cancer research.

[8]  B. Telfer,et al.  Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport , 2014, Molecular Cancer Therapeutics.

[9]  John Kurhanewicz,et al.  Hyperpolarized 13C MR for Molecular Imaging of Prostate Cancer , 2014, The Journal of Nuclear Medicine.

[10]  Chris Jones,et al.  Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma , 2014, PloS one.

[11]  Mark A. Hall,et al.  Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. , 2014, Cancer research.

[12]  Martin O. Leach,et al.  Comparison of three reference methods for the measurement of intracellular pH using 31P MRS in healthy volunteers and patients with lymphoma , 2013, NMR in biomedicine.

[13]  Paul D. Smith,et al.  Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[14]  Martin O. Leach,et al.  Model Free Approach to Kinetic Analysis of Real-Time Hyperpolarized 13C Magnetic Resonance Spectroscopy Data , 2013, PloS one.

[15]  John L Cleveland,et al.  Targeting lactate metabolism for cancer therapeutics. , 2013, Journal of Clinical Investigation.

[16]  J. Pouysségur,et al.  Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.

[17]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[18]  M. Leach,et al.  MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. , 2013, Cancer research.

[19]  A. Halestrap.  The SLC16 gene family - structure, role and regulation in health and disease. , 2013, Molecular aspects of medicine.

[20]  C. James,et al.  Reduced Phosphocholine and Hyperpolarized Lactate Provide Magnetic Resonance Biomarkers of Pi3k/akt/mtor Inhibition in Glioblastoma Neuro-onco Lo Gy , 2022 .

[21]  J. Griffiths,et al.  Histone deacetylase inhibition increases levels of choline kinase alpha and phosphocholine facilitating non-invasive imaging in human cancers , 2011 .

[22]  N M deSouza,et al.  Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? , 2012, British Journal of Cancer.

[23]  L. Ellis,et al.  Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. , 2012, Cancer research.

[24]  Franziska Hirschhaeuser,et al.  Lactate: a metabolic key player in cancer. , 2011, Cancer research.

[25]  J. Pouysségur,et al.  CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors , 2011, Proceedings of the National Academy of Sciences.

[26]  M. Leach,et al.  Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents , 2011, Cell cycle.

[27]  F. Gallagher,et al.  Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy , 2011, Magnetic resonance in medicine.

[28]  K. Brindle,et al.  Kinetic Modeling of Hyperpolarized 13C Label Exchange between Pyruvate and Lactate in Tumor Cells* , 2011, The Journal of Biological Chemistry.

[29]  A. Heerschap,et al.  31P Magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono‐ and diesters at 3 T in the human brain: relation with age and spatial differences , 2010, NMR in biomedicine.

[30]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[31]  John Kurhanewicz,et al.  Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Cancer research.

[32]  Lucio Frydman,et al.  Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells , 2009, Proceedings of the National Academy of Sciences.

[33]  I. Rayment,et al.  Structure, mechanism and regulation of pyruvate carboxylase. , 2008, The Biochemical journal.

[34]  T. Brown,et al.  In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi‐institutional trial , 2006, NMR in biomedicine.

[35]  Paul Workman,et al.  Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[36]  J. Koutcher,et al.  In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma. , 1997, Magnetic resonance imaging.

[37]  H. Thaler,et al.  Radiation dose-dependent changes in tumor metabolism measured by 31P nuclear magnetic resonance spectroscopy. , 1994, Cancer research.

[38]  J R Griffiths,et al.  Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation. , 1989, International journal of radiation oncology, biology, physics.